More than 16,000 dermatology trials were completed, ongoing, or planned by the end of 2025, with the Asia-Pacific region experiencing a nearly five-fold increase over the past decade. The field now accounts for around 8,000 trials in Asia-Pacific alone, matching North America and Europe combined.
Sanofi receives FDA approval for Dupixent to treat allergic fungal rhinosinusitis and gains European endorsement for Acoziborole Winthrop as a sleeping sickness treatment, which will be donated to WHO.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06620770 |
Impact of the Therapeutic Education Program "living with a Chronic Inflammatory Disease Under Biotherapy" on Patient Compliance and Quality of Life |
RECRUITING | |
| NCT05613712 |
Chronic Inflammatory Rheumatism: Management of Comorbidities in Ambulatory Medicine |
COMPLETED | |
| NCT05323110 |
Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers |
TERMINATED | PHASE1 |
| NCT04334031 |
Deployment o the Multidisciplinary Prospective Cohort Imminent |
RECRUITING | NA |
| NCT04327752 |
Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease |
COMPLETED | |
| NCT02332460 |
Infusion Related Reactions in Patients Receiving Infliximab |
UNKNOWN |
